Sweden
· Delayed Price · Currency is SEK Oncopeptides AB Statistics
Total Valuation
Oncopeptides AB has a market cap or net worth of SEK 309.87 million. The enterprise value is 253.23 million.
| Market Cap | 309.87M |
| Enterprise Value | 253.23M |
Important Dates
The next estimated earnings date is Thursday, May 15, 2025.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Oncopeptides AB has 215.19 million shares outstanding. The number of shares has increased by 84.13% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 215.19M |
| Shares Change (YoY) | +84.13% |
| Shares Change (QoQ) | +2.99% |
| Owned by Insiders (%) | 0.30% |
| Owned by Institutions (%) | 15.53% |
| Float | 183.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.57 |
| PB Ratio | 5.71 |
| P/TBV Ratio | 5.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.89 |
| EV / Sales | 8.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.23, with a Debt / Equity ratio of 2.25.
| Current Ratio | 4.23 |
| Quick Ratio | 4.14 |
| Debt / Equity | 2.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -398.17 |
Financial Efficiency
Return on equity (ROE) is -512.51% and return on invested capital (ROIC) is -102.84%.
| Return on Equity (ROE) | -512.51% |
| Return on Assets (ROA) | -73.43% |
| Return on Invested Capital (ROIC) | -102.84% |
| Return on Capital Employed (ROCE) | -147.01% |
| Revenue Per Employee | 395,600 |
| Profits Per Employee | -3.56M |
| Employee Count | 80 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 0.78 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.76% in the last 52 weeks. The beta is -0.45, so Oncopeptides AB's price volatility has been lower than the market average.
| Beta (5Y) | -0.45 |
| 52-Week Price Change | -68.76% |
| 50-Day Moving Average | 1.53 |
| 200-Day Moving Average | 1.95 |
| Relative Strength Index (RSI) | 40.63 |
| Average Volume (20 Days) | 495,700 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncopeptides AB had revenue of SEK 31.65 million and -284.61 million in losses. Loss per share was -1.71.
| Revenue | 31.65M |
| Gross Profit | 28.99M |
| Operating Income | -283.50M |
| Pretax Income | -284.21M |
| Net Income | -284.61M |
| EBITDA | -281.06M |
| EBIT | -283.50M |
| Loss Per Share | -1.71 |
Balance Sheet
The company has 178.54 million in cash and 121.89 million in debt, giving a net cash position of 56.64 million or 0.26 per share.
| Cash & Cash Equivalents | 178.54M |
| Total Debt | 121.89M |
| Net Cash | 56.64M |
| Net Cash Per Share | 0.26 |
| Equity (Book Value) | 54.29M |
| Book Value Per Share | 0.25 |
| Working Capital | 165.73M |
Cash Flow
| Operating Cash Flow | -260.57M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 91.59% |
| Operating Margin | -895.78% |
| Pretax Margin | -898.03% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oncopeptides AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -84.13% |
| Shareholder Yield | -84.13% |
| Earnings Yield | -91.85% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |